Overview

Conjugated linoleic acid (CLA) refers to a family of positional and geometric isomers of linoleic acid, an omega-6 polyunsaturated fatty acid. The two most biologically active isomers are c9,t11-CLA (rumenic acid) and t10,c12-CLA, which occur naturally in the fat of ruminant animals such as cattle, sheep, and goats. These isomers are produced by bacterial biohydrogenation of linoleic acid in the rumen and are found in meat, milk, and dairy products.

CLA gained widespread attention in the supplement industry following animal studies that demonstrated dramatic reductions in body fat. The t10,c12 isomer appears to be primarily responsible for the anti-obesity effects, working through mechanisms that include inhibition of lipoprotein lipase, increased fatty acid oxidation, and enhanced apoptosis in adipocytes. However, human clinical trials have yielded more modest results, with meta-analyses suggesting an average fat loss of approximately 0.05 kg per week at doses of 3–4 g per day. Some studies also indicate potential benefits for immune function and inflammatory markers.

While CLA is generally considered safe for short-term use, there are some concerns regarding metabolic effects. The t10,c12 isomer has been associated with increased insulin resistance, elevated inflammatory markers, and reduced HDL cholesterol in some human studies, particularly at higher doses. Supplemental CLA is typically derived from safflower oil or sunflower oil through chemical isomerization and usually contains a 50:50 mixture of the two main isomers. Consumers should be aware that the metabolic effects of supplemental CLA may differ from those of the naturally occurring CLA found in whole foods.

Mechanism of Action

Conjugated Dienoic Fatty Acid — Isomer-Specific Bioactivity

Conjugated linoleic acid (CLA) refers to a family of positional and geometric isomers of linoleic acid (18:2) characterized by conjugated double bonds (separated by a single carbon-carbon bond rather than the typical methylene-interrupted pattern). The two principal bioactive isomers are c9,t11-CLA (rumenic acid) — the predominant natural isomer (>80% of dietary CLA from ruminant fat) — and t10,c12-CLA, which is enriched in commercial CLA supplements (typically 50:50 mixtures). These isomers exert distinct and sometimes opposing metabolic effects, making isomer composition critical for predicting physiological outcomes (PMID: 15159244).

t10,c12-CLA — Adipocyte Lipid Metabolism

The t10,c12 isomer is the primary anti-adipogenic constituent, exerting its effects through multiple convergent mechanisms: (1) inhibition of stearoyl-CoA desaturase-1 (SCD-1), reducing monounsaturated fatty acid synthesis required for triglyceride assembly, (2) suppression of PPARgamma and C/EBPalpha transcription factor expression, blocking pre-adipocyte differentiation, (3) activation of AMPK in adipocytes, phosphorylating and inactivating acetyl-CoA carboxylase to reduce de novo lipogenesis, and (4) enhancement of fatty acid beta-oxidation through CPT1 upregulation. However, the t10,c12 isomer also induces insulin resistance in adipocytes by promoting inflammatory macrophage infiltration and NF-kB activation (PMID: 17490954).

c9,t11-CLA — Anti-Inflammatory & Immunomodulatory

The c9,t11 isomer (rumenic acid) activates PPARgamma in macrophages, promoting the anti-inflammatory M2 phenotype and suppressing NF-kB-mediated production of TNF-alpha, IL-6, and IL-1beta. It also serves as a precursor for conjugated metabolites that modulate eicosanoid synthesis, reducing pro-inflammatory PGE2 and TXA2 production while enhancing anti-inflammatory lipoxin formation (PMID: 16579853).

Body Composition & Lean Mass Preservation

Meta-analyses indicate CLA supplementation (3.2-6.4 g/day of mixed isomers) produces modest reductions in body fat mass (0.5-1.0 kg over 6-12 months) with concurrent preservation or slight increases in lean body mass, potentially through enhanced mitochondrial biogenesis via PGC-1alpha upregulation in skeletal muscle (PMID: 17490962).

Reconstitution Calculator

Research

Safety Profile

Safety Profile: CLA (Conjugated Linoleic Acid)

Overview Conjugated linoleic acid is a group of naturally occurring trans fatty acids found in meat and dairy products. It is widely marketed as a weight management supplement. While generally considered safe at moderate doses, CLA has notable metabolic effects that warrant careful consideration.

Common Side Effects

• Gastrointestinal disturbances including nausea, diarrhea, loose stools, and abdominal discomfort
• Fatigue and general malaise, particularly during initial supplementation
• Increased oxidative stress markers in some studies
• Mild dyspepsia and acid reflux

Serious Adverse Effects

• Insulin resistance: multiple clinical studies have shown CLA supplementation (particularly the trans-10, cis-12 isomer) may worsen insulin sensitivity
• Increased inflammatory markers (C-reactive protein) reported in some trials
• Hepatic fat accumulation observed in animal studies at high doses
• Potential reduction in HDL cholesterol levels
• Increased lipid peroxidation markers suggesting oxidative stress

Contraindications

• Type 2 diabetes or insulin resistance (may worsen glycemic control)
• Non-alcoholic fatty liver disease (NAFLD) due to potential hepatic lipid effects
• Metabolic syndrome (may exacerbate multiple metabolic parameters)
• Pregnancy and breastfeeding (insufficient safety data, potential metabolic effects on infant)
• Bleeding disorders due to potential antiplatelet activity

Drug Interactions

• Diabetes medications (metformin, insulin, sulfonylureas): CLA may counteract glucose-lowering effects by increasing insulin resistance
• Anticoagulants and antiplatelet drugs (warfarin, aspirin): may have additive effects on bleeding risk
• Statins and lipid-lowering medications: may alter lipid profile in unpredictable ways
• Hepatotoxic medications: theoretical additive liver stress

Special Populations

• Children should avoid CLA supplementation due to lack of pediatric safety data and potential metabolic effects
• Elderly patients with metabolic conditions should use with particular caution
• Obese individuals, often the target population, may be more susceptible to insulin resistance effects

Dosage Considerations

• Standard supplemental dose is 3-6 g/day, typically as a mixed isomer preparation
• Doses above 6 g/day are associated with increased adverse metabolic effects
• The specific isomer profile significantly affects the safety profile

Pharmacokinetic Profile